Chiauranib
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects[1].
Product Specifications
CAS Number
[1256349-48-0]
Product Name Alternative
Ibcasertib; CS2164
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
Aurora Kinase; c-Fms; c-Kit; Mitosis; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/chiauranib.html
Purity
99.28
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC=C1N)C2=C3C=CC(OC4=CC=NC5=CC(OC)=CC=C54)=CC3=CC=C2
Molecular Formula
C27H21N3O3
Molecular Weight
435.47
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Aurora B; PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
DYNC1H1 (Cytoplasmic Dynein 1 Heavy Chain 1, p22, DHC1, DNCL, DYHC, HL-3, DHC1a, DNCH1, DNECL, Dnchc1, SMALED1) discontinued
DYNC1H1 (Cytoplasmic Dynein 1 Heavy Chain 1, p22, DHC1, DNCL, DYHC, HL-3, DHC1a, DNCH1, DNECL, Dnchc1, SMALED1) discontinued
DYNC1H1 (Cytoplasmic Dynein 1 Heavy Chain 1, p22, DHC1, DNCL, DYHC, HL-3, DHC1a, DNCH1, DNECL, Dnchc1, SMALED1) discontinued
HEY1 (Hairy/Enhancer-of-Split Related with YRPW Motif 1, BHLHb31, CHF2, HERP2, HESR1, HRT-1, MGC1274, OAF1) (HRP)
HEY1 (Hairy/Enhancer-of-Split Related with YRPW Motif 1, BHLHb31, CHF2, HERP2, HESR1, HRT-1, MGC1274, OAF1) (HRP)